GLP-1/GIP dual agonist induces large decline in HbA1c, weight in type 2 diabetes
A once-weekly injectable GLP-1/GIP dual agonist reduced HbA1c by up to 2.65 percentage points at 48 weeks and lowered body weight for adults with type 2 diabetes and overweight or obesity, according to topline data from a phase 2 trial.
As Healio previously reported, enicepatide (Roche), formerly known as CT-388, reduced body weight by up to 22.5% more than placebo at 48 weeks for adults with overweight or obesity in a phase 2 trial. In new findings from another phase 2 trial named CT-388-104, enicepatide was assessed over 48 weeks in adults with type 2 diabetes plus overweight or obesity. The